Summarized by Masters of Longevity from PR Newswire.
Five-year data showed greater clinical benefit with continuous Leqembi in early Alzheimer's disease.

Key Takeaways
- Five years of Leqembi showed increasing cognitive benefit.
- Sixty-two percent of low-tau early patients showed improvement.
- ARIA-E events were most frequent early and then declined.



